Prime Therapeutics (Prime) once again had a robust presence at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025, which gathered more than 3,000 managed care leaders in National Harbor, Maryland, to discuss some of the most complex issues facing the health care industry. AMCP is the nation’s leading professional association that aims to help patients get the medications they need at a cost they can afford. This event annually attracts thousands of industry leaders, health care professionals and stakeholders committed to advancing the field. Prime’s teams will present research posters and educational sessions on health outcomes research. 

Press release 

Prime Therapeutics to present latest managed care pharmacy insights at AMCP Nexus 2025
Research on GLP-1 drugs, specialty therapies and more helps improve affordability in health care
Read more »

Stories

AMCP Nexus 2025: What’s new in retinal therapies? Prime experts share anti-VEGF advancements
As the efficacy and cost of these therapies become clear, so is the need for thoughtful managed care strategies, according to Prime Therapeutics thought leaders
Read more »

AMCP Nexus 2025: Prime’s GLP-1 persistence research recognized with platinum award
Prime Therapeutics researchers share more about award-winning real-world research
Read more »

AMCP Nexus 2025: A deep dive into prostate cancer treatment
Simone Ndujiuba, clinical oncology expert, shares strategies for managed care pharmacists to improve treatment
Read more »

AMCP Nexus 2025: Radiopharmaceuticals revolutionize cancer care
Prime Therapeutics experts share more about a targeted approach to tackling oncology
Read more »

Podcast

Treatment breakthroughs and managed care innovations highlighted at AMCP Nexus 2025
In the latest episode of the “Pharmacy Friends” podcast, join Prime’s research team for a preview of the industry-leading and award-winning research that will be presented at flagship industry event
Read more »
 

Research & Publications

AMCP Nexus 2025 research posters
Studies on GLP-1 drugs, specialty therapies and more help improve affordability in health care
Read more »
 

In the news

Managed Healthcare Executive: Real-World Study Shows $330,000 Cost Difference Between CAR T and BiTE Therapies | AMCP Nexus 2025
Bispecific T-cell engagers demonstrate lower total costs and reduced cytokine release and neurotoxicity rates compared with CAR T therapy for patients with follicular lymphoma
Read more »

Managed Healthcare Executive: Payers Are Bracing for the Specialty Trend of the Future | AMCP Nexus 2025
Prime Therapeutics executives discuss specialty drug trends at AMCP Nexus. Key areas include autoimmune therapies, multiple sclerosis treatments, and emerging cell and gene therapy challenges for payers
Read more »

Managed Healthcare Executive: Automated Prior Authorization Speeds Approval of GLP-1 Therapies | AMCP Nexus 2025
Prior authorization using integrated medical claims data helps diabetes patients get medications faster, with two-thirds processed automatically by July 2025 in this Prime Therapeutics analysis
Read more »